To observe the efficacy of combining recombinant human tumour
necrosis factor-Fc and methotrexate (MTX) in patients with disease-modifying
antirheumatic drug (DMARD)-resistant rheumatoid arthritis.
Collected 64
active RA patients with DMARD-resistant, according to patients’ gender, age,
duration and extent of disease activity, divided the 64 patients randomly into
comparable two groups. The experimental group within thirty-two
patients, were treated with twice-weekly subcutaneous etanercept (25 mg) and
meanwhile weekly oral MTX (15 mg).
The control group
within thirty-two patients, were treated with daily oral prednisone (5-10 mg)
and meanwhile weekly oral MTX (15 mg).Course of treatment is 12 weeks. Clinical
response was assessed using American College of Rheumatology (ACR) criteria.
No comments:
Post a Comment